CERO logo

CERo Therapeutics Holdings (CERO) Financials

Balance sheets

01 Sept 202401 June 202401 Mar 202401 Sept 202301 June 202301 Mar 202301 Mar 2022

Total Assets

$6.5 M(-11.9%)$7.4 M(-18.6%)$9.1 M--$9.6 M-

Current Assets

$3.7 M(-12.5%)$4.2 M(-22.8%)$5.5 M--$5.6 M-

Non Current Assets

$2.8 M(-11.1%)$3.1 M(-12.0%)$3.6 M--$4.0 M-

Total Liabilities

$10.2 M(+3.5%)$9.9 M(-24.4%)$13.0 M--$46.8 M-

Current Liabilities

$9.4 M(+7.3%)$8.8 M(-24.6%)$11.7 M--$1.9 M-

Long Term Liabilities

$771.5 K(-28.1%)$1.1 M(-22.2%)$1.4 M--$44.9 M-

Shareholders Equity

-$3.7 M(-49.2%)-$2.5 M(+37.6%)-$4.0 M---$37.3 M-

Book Value

-$7.3 M(+38.9%)-$11.9 M(+11.1%)-$13.4 M---$37.3 M-

Working Capital

-$5.7 M(-25.9%)-$4.5 M(+26.3%)-$6.2 M--$3.6 M-

Cash And Cash Equivalents

$3.4 M(-7.3%)$3.6 M(-20.6%)$4.6 M--$5.4 M-

Accounts Payable

$6.7 M(+5.0%)$6.3 M(-10.1%)$7.1 M--$868.9 K-

Accounts Receivable

-------

Short Term Debt

$1.0 M(-3.8%)$1.1 M(-10.3%)$1.2 M--$695.6 K-

Long Term Debt

$771.5 K(-28.1%)$1.1 M(-21.5%)$1.4 M--$2.2 M-

Total Debt

$1.8 M(-16.0%)$2.1 M(-16.2%)$2.6 M(+100.0%)$0.0(0%)$0.0(-100.0%)$2.9 M(+100.0%)$0.0

Debt To Equity

-0.5(+43.7%)-0.9(-35.9%)-0.6---0.1-

Current Ratio

0.4(-18.8%)0.5(+2.1%)0.5--2.9-

Quick Ratio

-------

Inventory

-------

Retained Earnings

-$71.6 M(-6.3%)-$67.4 M(-3.8%)-$64.9 M---$38.2 M-

PB Ratio

-1.8(-49.1%)-1.2(+64.1%)-3.3----

Income statements

01 Sept 202401 June 202401 Mar 202401 Sept 202301 June 202301 Mar 202301 Mar 2022

EPS

-$0.1(+40.0%)-$0.1--$0.1(+43.0%)-$0.2(+14.5%)-$0.3(+30.6%)-$0.4

TTM EPS

-$0.2(+14.6%)-$0.3--$0.6(-26.3%)-$0.5(-85.5%)-$0.3(+30.6%)-$0.4

Revenue

-------

TTM Revenue

-------

Total Expenses

$4.4 M(-14.5%)$5.1 M-$1.5 M(-36.4%)$2.4 M(-1.0%)$2.4 M(-31.0%)$3.5 M

Operating Expenses

$4.4 M(-14.5%)$5.1 M-$1.5 M(-36.4%)$2.4 M(-1.0%)$2.4 M(-31.0%)$3.5 M

Cost Of Goods Sold

-------

TTM Cost Of Goods Sold

-------

Gross Profit

-------

TTM Gross Profit

-------

Gross Margin

-------

Operating Profit

-$4.4 M(+14.5%)-$5.1 M--$1.5 M(+36.4%)-$2.4 M(+1.0%)-$2.4 M(+31.0%)-$3.5 M

TTM Operating Profit

-$9.6 M(-42.9%)-$6.7 M--$6.4 M(-31.6%)-$4.9 M(-99.0%)-$2.4 M(+31.0%)-$3.5 M

Operating Margin

-------

Net Income

-$4.2 M(-72.7%)-$2.4 M--$1.3 M(+35.5%)-$2.1 M(+14.2%)-$2.4 M(+30.6%)-$3.5 M

TTM Net Income

-$6.7 M(-75.8%)-$3.8 M--$5.9 M(-29.8%)-$4.5 M(-85.8%)-$2.4 M(+30.6%)-$3.5 M

Net Margin

-------

EBIT

-$4.4 M(-81.0%)-$2.4 M--$1.5 M(+36.4%)-$2.4 M(+1.0%)-$2.4 M(+31.0%)-$3.5 M

TTM EBIT

-$6.8 M(-72.3%)-$4.0 M--$6.4 M(-31.6%)-$4.9 M(-99.0%)-$2.4 M(+31.0%)-$3.5 M

EBITDA

-$4.4 M(-81.0%)-$2.4 M--$1.3 M(+41.3%)-$2.1 M(+1.3%)-$2.2 M(+34.0%)-$3.3 M

TTM EBITDA

-$6.8 M(-85.4%)-$3.7 M--$5.6 M(-29.2%)-$4.3 M(-98.7%)-$2.2 M(+34.0%)-$3.3 M

Selling, General & Administrative Expenses

$2.6 M(+8.0%)$2.4 M-$258.0 K(-78.9%)$1.2 M(+91.2%)$638.3 K(-13.3%)$736.3 K

TTM SG&A

$5.1 M(+88.0%)$2.7 M-$2.1 M(+13.9%)$1.9 M(+191.2%)$638.3 K(-13.3%)$736.3 K

Depreciation And Amortization

---$281.4 K(+1.4%)$277.5 K(+1.4%)$273.6 K(+8.8%)$251.4 K

TTM D&A

---$832.5 K(+51.1%)$551.1 K(+101.4%)$273.6 K(+8.8%)$251.4 K

Interest Expense

-$17.0 K-----

TTM Interest Expense

-$17.0 K-----

Income Tax

-------

TTM Income Tax

-------

PE Ratio

-------

PS Ratio

-------

Cashflow statements

01 Sept 202401 June 202401 Mar 202401 Sept 202301 June 202301 Mar 202301 Mar 2022

Cash From Operations

----$1.3 M(+36.4%)-$2.1 M(-44.4%)-$1.4 M(+62.1%)-$3.8 M

TTM CFO

----$4.8 M(-37.5%)-$3.5 M(-144.4%)-$1.4 M(+62.1%)-$3.8 M

Cash From Investing

-------$410.0 K

TTM CFI

-------$410.0 K

Cash From Financing

---$0.0(-100.0%)$566.5 K(+10794.2%)$5200.0(+100.0%)$0.0

TTM CFF

---$571.7 K(0%)$571.7 K(+10894.2%)$5200.0(+100.0%)$0.0

Free Cash Flow

----$1.3 M(+36.4%)-$2.1 M(-44.4%)-$1.4 M(+65.8%)-$4.2 M

TTM FCF

----$4.8 M(-37.5%)-$3.5 M(-144.4%)-$1.4 M(+65.8%)-$4.2 M

CAPEX

-------

TTM CAPEX

-------

Dividends Paid

-------

TTM Dividends Paid

-------

TTM Dividend Per Share

-------

TTM Dividend Yield

-------

Payout Ratio

-------